MedTrace Logo

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

NCT06596915 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2025-06-06

No results posted yet for this study

Summary

This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).

Conditions

Interventions

DRUG

BA1302

BA1302 administered intravenously

Sponsors & Collaborators

  • Shandong Boan Biotechnology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2025-12-31
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06596915 on ClinicalTrials.gov